Several recent events highlight an increase in the pace of innovation in rapid infectious disease testing. In July, Accelerate Diagnostics Inc. filed a De Novo request to the US Food and Drug Administration for Evaluation of Automatic Class III Designation of its system for pathogen identification and antibiotic susceptibility testing (AST). A week and a half earlier, Cepheid obtained clearance from FDA for expanded claims to its Xpert Carba-R test for detecting carbapenem resistance genes in multidrug-resistant organisms using rectal swabs in addition to bacterial isolates, significantly cutting testing time. Two months earlier, Luminex Corp. completed a tender offer for bloodstream infectious disease test specialist Nanosphere Inc. for $77 million. [See Deal] Also in May, the Merck Global Health Innovation Fund (Merck GHI) increased its investment in OpGen Inc. to help fund OpGen’s bioinformatics-heavy platform for infection detection and control. [See Deal] These moves after Roche drew attention to the space last summer when it paid $190 million up front and promised another $235 million in product-related milestones for GeneWEAVE Biosciences Inc. and its platform for rapidly detecting multidrug-resistant organisms and analyzing AST or resistance. [See Deal]
Rapid Infectious Disease Testing Picks Up Speed
Recent regulatory events and dealmaking highlight an increase in the pace of innovation in rapid infectious disease testing.
More from Innovation
AI-related deal activitiy in the first quarter of 2025 was punctuated by a last-minute $600m raise for Isomorphic Labs.
The process of manufacturing medicines can often be complex, expensive and harmful to the environment. Initiatives like RESILIENCE UK are seeking to simplify this process, utilizing VR technology to create a more sustainable learning environment for both students and companies.
Antag CEO Joerg Moeller talked to In Vivo about the young company’s gilded roots, and how its GIP receptor antagonist asset will differentiate in the crowded obesity market.
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.
More from In Vivo
Despite the significant presence of East Asian professionals in the pharmaceutical industry, their representation in top leadership roles remains disproportionately low. This disparity can be attributed to cultural bias, limited access to influential networks, and systemic barriers within corporate structures.
The world’s biggest pharmaceutical companies mostly saw growth in 2024 but 2025 promises to be more of a mixed bag with headwinds including losses of exclusivity, Medicare Part D redesign and challenges in the Chinese market.
Farideh Bischoff, chief medical officer of Heranova Lifesciences, discusses the urgent need for better diagnostic options and the latest innovations transforming care for endometriosis patients.